May 2nd 2024
The new research will compare eblasakimab to dupilumab and lebrikizumab.
FDA Approves Historic Roflumilast Foam 0.3% For Seborrheic Dermatitis
December 15th 2023Roflumilast foam 0.3% is the first FDA-approved drug for seborrheic dermatitis with a new mechanism of action in over 2 decades. Christopher Bunick, MD, PhD; Shawn Kwatra, MD; and Peter Lio, MD, share expert insights.